Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Acalabrutinib in Relapsed/Refractory Mantle Cell Lymphoma
NCT03946878Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2019
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Complete Response at 16 weeks. Started Aug 2019; status: active, not recruiting.
02
Drugs
venetoclaxacalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03946878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946878.